Through 168 weeks, the percentage of patients who achieved and maintained HIV-1 RNA less than 400 copies/mL was 48 percent (EFV+ZDV+LAM), 40 percent (EFV+IDV) and 29 percent (IDV+ZDV+LAM) using an intent-to treat, time to loss of virologic response analysis.
What does TLOVR stand for?
TLOVR stands for Time to Loss of Virologic Response (virology, immunology)
This definition appears very rarely and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
- The Love of Siam (film)
- Transient Lower Oesophageal Sphincter Relaxations
- Theological Lexicon of the Old Testament
- Top Libertarians on Twitter
- The Lady Of The Hour
- The Lady of the House
- The Loneliness of the Long Distance Runner (Alan Sillitoe book)
- The Lord of the Rings (Tolkien book/movie)
- The Lord of the Rings: the Return of the King (book, video game, and movie)
- The Last of Us (video game)
- The Lords of War (gaming clan)
- Total Loss of Water (main and emergency feedwater)
- The Likes of You (Los Angeles, CA band)
- The Legend of Zelda (game)
- The Legend of Zelda: Skyward Sword (gaming)
- The Legend of Zelda: Ocarina of Time (video game)
- The Legend of Zelda: Phantom Hourglass (game)
- The Legend of Zelda the Wind Waker (gaming)
- Tactical Leadership Program
- Tanzania Labor Party
Samples in periodicals archive:
Time to loss of virologic response was also longer in the combination group, with a hazard ratio of 2.
After 96 weeks of treatment (n=463), 75 percent of Viread/Emtriva/Sustiva patients compared to 62 percent of Combivir/Sustiva patients achieved and maintained viral load less than 400 copies/mL using the Time to Loss of Virologic Response algorithm (TLOVR) (p=0.
The primary endpoint is the proportion of patients achieving and maintaining viral load reductions to less than 400 copies/mL at week 48, using the Time to Loss of Virologic Response (TLOVR) algorithm, as specified in FDA guidance.
Preliminary results show a statistically significant difference favoring Viread/Emtriva in the percentage of patients who achieved and maintained HIV RNA less than 400 copies/mL at 24 weeks, based on the FDA Time to Loss of Virologic Response algorithm (TLOVR).